Cargando…
Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening
Lyme disease is the most common zoonotic bacterial disease in North America. It is estimated that >300,000 cases per annum are reported in USA alone. A total of 10%–20% of patients who have been treated with antibiotic therapy report the recrudescence of symptoms, such as muscle and joint pain, p...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827596/ https://www.ncbi.nlm.nih.gov/pubmed/27103785 http://dx.doi.org/10.2147/DDDT.S101486 |
_version_ | 1782426489762873344 |
---|---|
author | Pothineni, Venkata Raveendra Wagh, Dhananjay Babar, Mustafeez Mujtaba Inayathullah, Mohammed Solow-Cordero, David Kim, Kwang-Min Samineni, Aneesh V Parekh, Mansi B Tayebi, Lobat Rajadas, Jayakumar |
author_facet | Pothineni, Venkata Raveendra Wagh, Dhananjay Babar, Mustafeez Mujtaba Inayathullah, Mohammed Solow-Cordero, David Kim, Kwang-Min Samineni, Aneesh V Parekh, Mansi B Tayebi, Lobat Rajadas, Jayakumar |
author_sort | Pothineni, Venkata Raveendra |
collection | PubMed |
description | Lyme disease is the most common zoonotic bacterial disease in North America. It is estimated that >300,000 cases per annum are reported in USA alone. A total of 10%–20% of patients who have been treated with antibiotic therapy report the recrudescence of symptoms, such as muscle and joint pain, psychosocial and cognitive difficulties, and generalized fatigue. This condition is referred to as posttreatment Lyme disease syndrome. While there is no evidence for the presence of viable infectious organisms in individuals with posttreatment Lyme disease syndrome, some researchers found surviving Borrelia burgdorferi population in rodents and primates even after antibiotic treatment. Although such observations need more ratification, there is unmet need for developing the therapeutic agents that focus on removing the persisting bacterial form of B. burgdorferi in rodent and nonhuman primates. For this purpose, high-throughput screening was done using BacTiter-Glo assay for four compound libraries to identify candidates that stop the growth of B. burgdorferi in vitro. The four chemical libraries containing 4,366 compounds (80% Food and Drug Administration [FDA] approved) that were screened are Library of Pharmacologically Active Compounds (LOPAC1280), the National Institutes of Health Clinical Collection, the Microsource Spectrum, and the Biomol FDA. We subsequently identified 150 unique compounds, which inhibited >90% of B. burgdorferi growth at a concentration of <25 µM. These 150 unique compounds comprise many safe antibiotics, chemical compounds, and also small molecules from plant sources. Of the 150 unique compounds, 101 compounds are FDA approved. We selected the top 20 FDA-approved molecules based on safety and potency and studied their minimum inhibitory concentration and minimum bactericidal concentration. The promising safe FDA-approved candidates that show low minimum inhibitory concentration and minimum bactericidal concentration values can be chosen as lead molecules for further advanced studies. |
format | Online Article Text |
id | pubmed-4827596 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-48275962016-04-21 Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening Pothineni, Venkata Raveendra Wagh, Dhananjay Babar, Mustafeez Mujtaba Inayathullah, Mohammed Solow-Cordero, David Kim, Kwang-Min Samineni, Aneesh V Parekh, Mansi B Tayebi, Lobat Rajadas, Jayakumar Drug Des Devel Ther Original Research Lyme disease is the most common zoonotic bacterial disease in North America. It is estimated that >300,000 cases per annum are reported in USA alone. A total of 10%–20% of patients who have been treated with antibiotic therapy report the recrudescence of symptoms, such as muscle and joint pain, psychosocial and cognitive difficulties, and generalized fatigue. This condition is referred to as posttreatment Lyme disease syndrome. While there is no evidence for the presence of viable infectious organisms in individuals with posttreatment Lyme disease syndrome, some researchers found surviving Borrelia burgdorferi population in rodents and primates even after antibiotic treatment. Although such observations need more ratification, there is unmet need for developing the therapeutic agents that focus on removing the persisting bacterial form of B. burgdorferi in rodent and nonhuman primates. For this purpose, high-throughput screening was done using BacTiter-Glo assay for four compound libraries to identify candidates that stop the growth of B. burgdorferi in vitro. The four chemical libraries containing 4,366 compounds (80% Food and Drug Administration [FDA] approved) that were screened are Library of Pharmacologically Active Compounds (LOPAC1280), the National Institutes of Health Clinical Collection, the Microsource Spectrum, and the Biomol FDA. We subsequently identified 150 unique compounds, which inhibited >90% of B. burgdorferi growth at a concentration of <25 µM. These 150 unique compounds comprise many safe antibiotics, chemical compounds, and also small molecules from plant sources. Of the 150 unique compounds, 101 compounds are FDA approved. We selected the top 20 FDA-approved molecules based on safety and potency and studied their minimum inhibitory concentration and minimum bactericidal concentration. The promising safe FDA-approved candidates that show low minimum inhibitory concentration and minimum bactericidal concentration values can be chosen as lead molecules for further advanced studies. Dove Medical Press 2016-04-01 /pmc/articles/PMC4827596/ /pubmed/27103785 http://dx.doi.org/10.2147/DDDT.S101486 Text en © 2016 Pothineni et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Pothineni, Venkata Raveendra Wagh, Dhananjay Babar, Mustafeez Mujtaba Inayathullah, Mohammed Solow-Cordero, David Kim, Kwang-Min Samineni, Aneesh V Parekh, Mansi B Tayebi, Lobat Rajadas, Jayakumar Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening |
title | Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening |
title_full | Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening |
title_fullStr | Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening |
title_full_unstemmed | Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening |
title_short | Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening |
title_sort | identification of new drug candidates against borrelia burgdorferi using high-throughput screening |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827596/ https://www.ncbi.nlm.nih.gov/pubmed/27103785 http://dx.doi.org/10.2147/DDDT.S101486 |
work_keys_str_mv | AT pothinenivenkataraveendra identificationofnewdrugcandidatesagainstborreliaburgdorferiusinghighthroughputscreening AT waghdhananjay identificationofnewdrugcandidatesagainstborreliaburgdorferiusinghighthroughputscreening AT babarmustafeezmujtaba identificationofnewdrugcandidatesagainstborreliaburgdorferiusinghighthroughputscreening AT inayathullahmohammed identificationofnewdrugcandidatesagainstborreliaburgdorferiusinghighthroughputscreening AT solowcorderodavid identificationofnewdrugcandidatesagainstborreliaburgdorferiusinghighthroughputscreening AT kimkwangmin identificationofnewdrugcandidatesagainstborreliaburgdorferiusinghighthroughputscreening AT saminenianeeshv identificationofnewdrugcandidatesagainstborreliaburgdorferiusinghighthroughputscreening AT parekhmansib identificationofnewdrugcandidatesagainstborreliaburgdorferiusinghighthroughputscreening AT tayebilobat identificationofnewdrugcandidatesagainstborreliaburgdorferiusinghighthroughputscreening AT rajadasjayakumar identificationofnewdrugcandidatesagainstborreliaburgdorferiusinghighthroughputscreening |